Jurickson Profar's remarkable career resurgence has come to a crashing halt. The Atlanta Braves outfielder has been suspended 162 games — effectively the entire 2026 season — after testing positive for exogenous testosterone and its metabolites, Major League Baseball announced on March 3. It is the second time in less than a year that Profar has failed a performance-enhancing drug test.

The suspension is automatic under MLB's Joint Drug Prevention and Treatment Program, which mandates a full-season ban for a second PED offense. Profar will forfeit his entire $15 million salary for the 2026 campaign, a devastating financial blow on top of the reputational damage. He is also barred from representing the Netherlands in the 2026 World Baseball Classic, an event he had been expected to headline for the Dutch national team.

Profar's first violation came during the 2025 season, when he tested positive for human chorionic gonadotropin, a substance frequently linked to testosterone manipulation. That infraction resulted in an 80-game suspension that sidelined him for roughly half the year. The fact that he has now tested positive a second time, for a different but related substance, raises serious questions about the 33-year-old's future in the sport.

Since 2014, only six players have received a full-season PED ban under the current program. It is a distinction no player wants, and it places Profar in uncomfortable company at a time when baseball continues to fight for the integrity of its competition.

The timing could hardly be worse for the Braves. Profar signed a three-year, $42 million contract with Atlanta after a breakout 2024 campaign with the San Diego Padres, where he earned his first career All-Star selection and took home a Silver Slugger Award. He was supposed to be a cornerstone of the Braves' retooled outfield, a veteran presence capable of anchoring the lineup. Instead, the organization is left scrambling to fill a massive hole in its roster before Opening Day.

Atlanta will now need to explore both internal and external options to replace Profar's production. The Braves had already invested heavily in the offseason with the expectation that Profar would be a lineup fixture. His absence forces the front office into reactive mode during a period when the best available free agents have long since signed and trade options are limited.

For Profar personally, the road back will be steep. He spent years bouncing between organizations, never quite living up to the promise that made him one of the most celebrated prospects in baseball as a teenager with the Texas Rangers. When he finally put it all together in San Diego in 2024, it felt like a redemption story for the ages. Now, that narrative has been irreparably altered.

If and when Profar returns, he will be 34 years old, more than a full season removed from competitive play, and carrying the stigma of two PED violations. The remaining year on his contract will be overshadowed by skepticism, and any future accomplishments will be viewed through the lens of these suspensions.

Baseball has always been a sport that prizes its records and its sense of fair play. Profar's case serves as a sobering reminder that the consequences of violating that trust are swift, severe, and lasting. The Braves will move on. The question is whether Profar ever truly can.